Related references
Note: Only part of the references are listed.International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics
Jose-Francisco Rocha et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Personalized Medicine in Parkinson's Disease: Time to Be Precise
Nataliya Titova et al.
MOVEMENT DISORDERS (2017)
Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial
Andrew J. Lees et al.
JAMA NEUROLOGY (2017)
A new PAMPA model using an in-house brain lipid extract for screening the blood-brain barrier permeability of drug candidates
Joana Bicker et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
Joaquim J. Ferreira et al.
LANCET NEUROLOGY (2016)
Effect of 3 Single-Dose Regimens of Opicapone on Levodopa Pharmacokinetics, Catechol-O-Methyltransferase Activity and Motor Response in Patients With Parkinson Disease
Jose-Francisco Rocha et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat
M. J. Bonifacio et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Catechol-O-Methyltransferase Inhibitors in Parkinson's Disease
Thomas Mueller
DRUGS (2015)
Effect of opicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity and motor fluctuations in patients with Parkinson's disease
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Effect of entacapone on colon motility and ion transport in a rat model of Parkinson's disease
Li-Sheng Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Clinical Spectrum of Levodopa-Induced Complications
Camila Catherine Aquino et al.
MOVEMENT DISORDERS (2015)
Levodopa Therapy for Parkinson's Disease: Pharmacokinetics and Pharmacodynamics
Peter A. LeWitt
MOVEMENT DISORDERS (2015)
Clinical pharmacology review of safinamide for the treatment of Parkinson's disease
Margherita Fabbri et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2015)
Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations
Jose-Francisco Rocha et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Medicinal Chemistry of Catechol O-Methyltransferase (COMT) Inhibitors and Their Therapeutic Utility
Laszlo E. Kiss et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease
Rupam Borgohain et al.
MOVEMENT DISORDERS (2014)
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor
M. J. Bonifacio et al.
NEUROPHARMACOLOGY (2014)
Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects
Jose Francisco Rocha et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Pharmacokinetics, Pharmacodynamics and Tolerability of Opicapone, a Novel Catechol-O-Methyltransferase Inhibitor, in Healthy Subjects
Luis Almeida et al.
CLINICAL PHARMACOKINETICS (2013)
Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease
J. J. Ferreira et al.
EUROPEAN JOURNAL OF NEUROLOGY (2013)
Efficacy and safety of opicapone, a new COMT-inhibitor, for the treatment of motor fluctuations in Parkinson's Disease patients: BIPARK-II study
A. Lees et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2013)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Late-stage Parkinson disease
Miguel Coelho et al.
NATURE REVIEWS NEUROLOGY (2012)
The COMT Val158Met Polymorphism Affects the Response to Entacapone in Parkinson's Disease: A Randomized Crossover Clinical Trial
Jean-Christophe Corvol et al.
ANNALS OF NEUROLOGY (2011)
A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes
Olivier Rascol et al.
LANCET NEUROLOGY (2011)
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2011)
2.241 COMPUTATION OF BINDING AFFINITY OF CATECHOL-O-METHYLTRANSFERASE-OPICAPONE COMPLEXES
N. Palma et al.
PARKINSONISM & RELATED DISORDERS (2011)
Discovery of a Long-Acting, Peripherally Selective Inhibitor of Catechol-O-methyltransferase
Laszlo E. Kiss et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A reassessment of risks and benefits of dopamine agonists in Parkinson's disease
Angelo Antonini et al.
LANCET NEUROLOGY (2009)
Double-Blind Trial of Levodopa/Carbidopa/Entacapone Versus Levodopa/Carbidopa in Early Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2009)
Naturalistic evaluation of entacapone in patients with signs and symptoms of L-dopa wearing-off
M. Jog et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Treatment of levodopa-induced motor complications
Fabrizio Stocchi et al.
MOVEMENT DISORDERS (2008)
Pharmacokinetics and pharmacodynamics of levodopa
John G. Nutt
MOVEMENT DISORDERS (2008)
Ropinirole 24-hour prolonged release - Randomized, controlled study in advanced Parkinson disease
R. Pahwa et al.
NEUROLOGY (2007)
Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients:: the effects of an early therapeutic intervention
F. Grandas et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
E. R. Dorsey et al.
NEUROLOGY (2007)
Management of motor complications in advanced Parkinson's disease
Eldad Melamed et al.
MOVEMENT DISORDERS (2007)
Selegiline slows the progression of the symptoms of Parkinson disease
S Pålhagen et al.
NEUROLOGY (2006)
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O Rascol et al.
LANCET (2005)
Impact of the motor complications of Parkinson's disease on the quality of life
S Chapuis et al.
MOVEMENT DISORDERS (2005)
Treatment of end-of-dose wearing-off in Parkinson's disease: Stalevo (R) (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess (R)/Comtan (R) (Entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment
DJ Brooks et al.
EUROPEAN NEUROLOGY (2005)
Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
Y Mizuno et al.
MOVEMENT DISORDERS (2003)
Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal Levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study)
WH Poewe et al.
ACTA NEUROLOGICA SCANDINAVICA (2002)
F-18-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease
R Ceravolo et al.
SYNAPSE (2002)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Dyskinesias and motor fluctuations in Parkinson's disease - A community-based study
A Schrag et al.
BRAIN (2000)
Share Paper
